Dexcom, Companion Medical will share glucose, insulin data

Dexcom (NSDQ:DXCM) and Companion Medical have announced a collaboration to enable a direct exchange of continuous glucose monitoring (CGM) data from Dexcom with insulin data from InPen into both companies’ software applications.

Companion made a partnership deal with Glooko this week to integrate data from its InPen smart insulin injection pen into Glooko’s diabetes data management system and mobile application.

Dexcom and Companion Medical said they are working on developing a seamless data transfer of both insulin and glucose information to improve in-the-moment decisions for those managing their diabetes with multiple daily injections. Advanced decision support requires multiple inputs, including current glucose, glucose trend, carbohydrate intake, accurate insulin dosing and insulin-on-board.

Dexcom and Companion Medical will initially enable InPen users to display long-acting and rapid-acting insulin data in the Dexcom Clarity Diabetes Management Software. Dexcom CGM data is currently available in the Companion Medical Insights by InPen report. This integration enables health care providers to access a combined, comprehensive view of a patient’s therapy plan, increasing the effectiveness of how and when patients should dose and paving the way for improved and transparent treatment decisions, the companies said.

The InPen/Clarity report integration will be launched and available for preview at the  American Diabetes Association conference, which runs today through Wednesday, June 12, in San Francisco. Both companies said they are actively developing their real-time integrated systems.

“These decisions are synchronous to the person living with diabetes, which provides a compelling opportunity for our teams to work together,” said Steve Pacelli, EVP of strategy and corporate development for Dexcom, in a news release.

“Improving outcomes for people on multiple daily injections requires bringing together the two critical factors of diabetes management — glucose and insulin — in real-time. We are the first two companies with the technology capable of providing an integrated solution,” added Companion Medical CEO Sean Saint.